联环药业：重酒石酸去甲肾上腺素注射液获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of a new drug, which is aimed at managing acute hypotensive states and serves as an auxiliary treatment for cardiac arrest and severe hypotension [1] Group 1 - The newly approved drug is heavy tartrate norepinephrine injection [1] - The drug is specifically indicated for certain acute low blood pressure conditions [1] - It is also utilized as a supportive treatment in cases of cardiac arrest and severe hypotension [1]